Enanta Pharmaceuticals, Inc. (ENTA)
13.60
-0.20
(-1.45%)
USD |
NASDAQ |
Aug 28, 16:00
13.58
-0.02
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals Debt to Equity Ratio : 1.801 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.801 |
| March 31, 2026 | 1.601 |
| December 31, 2025 | 1.526 |
| September 30, 2025 | 3.107 |
| June 30, 2025 | 2.612 |
| March 31, 2025 | 2.311 |
| December 31, 2024 | 1.979 |
| September 30, 2024 | 1.755 |
| June 30, 2024 | 1.519 |
| March 31, 2024 | 1.384 |
| December 31, 2023 | 1.121 |
| September 30, 2023 | 1.026 |
| June 30, 2023 | 0.9705 |
| March 31, 2023 | 0.1092 |
| December 31, 2022 | 0.089 |
| September 30, 2022 | 0.083 |
| June 30, 2022 | 0.0778 |
| March 31, 2022 | 0.0548 |
| December 31, 2021 | 0.0545 |
| September 30, 2021 | 0.0171 |
| June 30, 2021 | 0.0195 |
| March 31, 2021 | 0.0213 |
| December 31, 2020 | 0.0226 |
| September 30, 2020 | 0.021 |
| June 30, 2020 | 0.0217 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0221 |
| December 31, 2019 | 0.0223 |
| September 30, 2019 | 0.004 |
| June 30, 2019 | 0.0041 |
| March 31, 2019 | 0.0043 |
| December 31, 2018 | 0.0044 |
| September 30, 2018 | 0.0049 |
| June 30, 2018 | 0.0051 |
| March 31, 2018 | 0.0056 |
| December 31, 2017 | 0.0059 |
| September 30, 2017 | 0.004 |
| June 30, 2017 | 0.0025 |
| March 31, 2017 | 0.0025 |
| December 31, 2016 | 0.0025 |
| September 30, 2016 | 0.0026 |
| June 30, 2016 | 0.0026 |
| March 31, 2016 | 0.0027 |
| December 31, 2015 | 0.0028 |
| September 30, 2015 | 0.0032 |
| June 30, 2015 | 0.0016 |
| March 31, 2015 | 0.0008 |
| December 31, 2014 | 0.0009 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Perspective Therapeutics, Inc. | 0.0122 |
| AbbVie, Inc. | -11.93 |
| Coherus Oncology, Inc. | 0.8905 |
| BridgeBio Pharma, Inc. | -1.353 |
| RenovoRx, Inc. | 0.0434 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 296.87M |
| Total Liabilities (Quarterly) | 195.80M |
| Shareholders Equity (Quarterly) | 101.07M |
| Current Ratio | 3.759 |
| Net Debt Paydown Yield | 1.61% |